These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22330952)

  • 1. Considerations for the use of proton-pump inhibitors in older adults.
    Desilets AR; Asal NJ; Dunican KC
    Consult Pharm; 2012 Feb; 27(2):114-20. PubMed ID: 22330952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis.
    Giuliano C; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2012 May; 5(3):337-44. PubMed ID: 22697595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
    Lau YT; Ahmed NN
    Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitors: potential adverse effects.
    Abraham NS
    Curr Opin Gastroenterol; 2012 Nov; 28(6):615-20. PubMed ID: 23010681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools.
    Hauben M; Horn S; Reich L; Younus M
    Int J Infect Dis; 2007 Sep; 11(5):417-22. PubMed ID: 17336566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications and safety of proton pump inhibitor drug use in patients with cancer.
    Triadafilopoulos G; Roorda AK; Akiyama J
    Expert Opin Drug Saf; 2013 Sep; 12(5):659-72. PubMed ID: 23647006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
    Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
    Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of proton pump inhibitor exposure.
    Yang YX; Metz DC
    Gastroenterology; 2010 Oct; 139(4):1115-27. PubMed ID: 20727892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adverse events associated with long-term use of proton pump inhibitors].
    Reimer C; Bytzer P
    Ugeskr Laeger; 2012 Sep; 174(39):2289-93. PubMed ID: 23006222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia.
    de Jager CP; Wever PC; Gemen EF; van Oijen MG; van Gageldonk-Lafeber AB; Siersema PD; Kusters GC; Laheij RJ
    Aliment Pharmacol Ther; 2012 Nov; 36(10):941-9. PubMed ID: 23034135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis.
    Deshpande A; Pant C; Pasupuleti V; Rolston DD; Jain A; Deshpande N; Thota P; Sferra TJ; Hernandez AV
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):225-33. PubMed ID: 22019794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed.
    Hermos JA; Young MM; Fonda JR; Gagnon DR; Fiore LD; Lawler EV
    Clin Infect Dis; 2012 Jan; 54(1):33-42. PubMed ID: 22100573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
    Stevens V; Dumyati G; Brown J; Wijngaarden E
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events.
    MacLaren R; Kassel LE; Kiser TH; Fish DN
    Expert Opin Drug Saf; 2015 Feb; 14(2):269-80. PubMed ID: 25423448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease.
    Choudhry MN; Soran H; Ziglam HM
    QJM; 2008 Jun; 101(6):445-8. PubMed ID: 18411220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.
    Aseeri M; Schroeder T; Kramer J; Zackula R
    Am J Gastroenterol; 2008 Sep; 103(9):2308-13. PubMed ID: 18702653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitor use and the antifracture efficacy of alendronate.
    Abrahamsen B; Eiken P; Eastell R
    Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perils and pitfalls of long-term effects of proton pump inhibitors.
    Wilhelm SM; Rjater RG; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):443-51. PubMed ID: 23927671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect?
    Kushner PR; Peura DA
    Adv Ther; 2011 May; 28(5):367-88. PubMed ID: 21484335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.